[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-thyroid-nodule\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-thyroid-nodule":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100611191","percutaneous-thermo-ablation-for-the-treatment-of-benign-thyroid-nodules-100611191",false,"NCT07237373","Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules","Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules: a Prospective Multicentric Study","BIRRO-TA","Inclusion Criteria:\n\n* \\> 18 years old\n* 'Eastern Cooperative Oncology Group' (ECOG) performance status of 0 or 1\n* Symptomatic benign thyroid nodules with compressive\u002Fcosmetic complaints OR autonomously functioning thyroid nodules with subclinical hyperthyreosis or thyrotoxicosis proven on scintigraphy.\n* No cutoff in nodule size.\n* Solid component \\> 20%, and benign cytology (Bethesda II) in 1 (EUTIRADS 3) or 2 (EUTIRADS 4) separate cytological assessments. In the case of a proven \"hot\" nodule on scintigraphy, no biopsy is required.\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Purely cystic nodule\n* Severe comorbidity which limits the further life expectancy of the patient to \\\u003C 2 years (opinion of the physician)\n* Malignancies \\\u003C2 years ago except for non-melanoma skin cancer and non-muscle invasive bladder cancer.\n* Lack of compliance\n* Malignant or suspicious thyroid nodules or nodules that are confluent in a compressive lobar mass\n* Contralateral vocal cord paralysis\n* Anticoagulant therapy that could not be suspended\n* Unresolvable coagulation disorders\n* Absence of consent of the patient","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to learn if radiofrequency ablation (RFA), a minimally invasive thermoablation technique, can safely reduce symptoms and improve quality of life in adults with symptomatic benign thyroid nodules or autonomously functioning thyroid nodules.\n\nThe main questions it aims to answer are:\n\n* Does RFA improve health-related quality of life (HRQoL) as measured by the ThyPRO-39 questionnaire?\n* Does RFA effectively reduce nodule volume and related symptoms (compressive or cosmetic)?\n\nParticipants will:\n\n* Undergo a radiofrequency ablation procedure of the thyroid nodule performed under ultrasound guidance in an outpatient setting.\n* Complete quality of life questionnaires (ThyPRO-39) before treatment and at follow-up visits.\n\nAttend follow-up visits at 1, 3, 6, and 12 months with:\n\n* Ultrasound assessments of the thyroid nodule\n* Symptom and cosmetic scoring\n* Blood tests to monitor thyroid function\n* Safety checks for possible complications",[26],"Benign Thyroid Nodule",[28,29,30,31],"benign thyroid nodule","radiofrequency ablation","interventional radiology","percutaneous thermoablation","RECRUITING","2026-04-23",{"date":35,"type":36},"2026-04-29","ACTUAL",{"date":38,"type":36},"2026-03-03",{"date":40,"type":21},"2031-04-01",{"name":42,"class":43},"University Hospital, Ghent","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100611055","intravenous-sedation-and-analgesia-versus-local-anesthesia-during-microwave-ablation-of-benign-thyroid-nodules-100611055","NCT07235605","Intravenous Sedation and Analgesia Versus Local Anesthesia During Microwave Ablation of Benign Thyroid Nodules","Inclusion Criteria:\n\n* Aged 20 to 60 years\n* Both sexes\n* American Society of Anesthesiologists (ASA)I-II.\n\nExclusion Criteria:\n\n* Patients with chronic pain\n* long-term alcoholism or taking tranquilizers or antipsychotic drugs\n* Patients with malignant thyroid nodules\n* Thyroid nodules compressing the trachea\n* Hypertension in which BP was not controlled below 140\u002F90 mmHg\n* Patients with reflux esophagitis","20 Years","60 Years",{"count":53,"type":21},52,"INTERVENTIONAL",[56],"NA","The participants will be randomized into 2 equal groups by a computer-generated random numbers table, named group A and B. An independent data manager of computer-generated software will be responsible for randomization, assigning the participants to the groups using sequentially numbered, sealed, opaque envelopes containing computer-generated random numbers, accessible only to the anesthesiologist. The subjects will be randomly allocated to one of the two groups.\n\nGroup A: The participants will receive moderate to deep sedation.\n\nGroup B: The participants will receive perithyroidal local anesthesia.\n\nHistory taking, clinical examination, and routine laboratory investigation will be performed preoperatively, and the participants will be instructed to fast for 6 hours preoperatively for solids and 2 hours for clear fluids. On arrival at the operation room, intravenous access will be established. ECG, noninvasive blood pressure, and arterial oxygen saturation will be monitored routinely. The Numerical Rating Scale (NRS) will be used to assess pain intensity. Preoperatively, all study subjects will be trained to use NRS pain scores.\n\nIn the intervention radiology room, a peripheral 20 G intravenous (IV) cannula will be inserted. The baseline parameters of five lead electrocardiogram (ECG), noninvasive blood pressure, and peripheral oxygen saturation will be recorded. A nasal oxygen cannula will be applied with a flow of 3 L\u002Fmin.\n\nIn group A, participants will receive drugs resulting in moderate to deep sedation, tailored to the specific portions of the procedure, which may offer potential benefits. This approach could provide participants with a potentially painless experience by utilizing moderate sedation during needle placement and deep sedation during the ablation phase. Additionally, this combination approach may minimize the risk of respiratory depression (which can be associated with TIVA and deep sedation) while promoting rapid recovery. The participants will receive premedication with the alpha-2-agonists, dexmedetomidine (2.5 μg\u002Fkg IV).\n\nThe sedation combination approach will involve the use of fentanyl (1 microgram\u002Fkg), ketamine (1 milligram\u002F kg followed by 0.5 milligram\u002Fkg if repeated doses are necessary to accomplish longer duration) and propofol (Loading dose: 0.5-1 mg\u002Fkg, followed by top up doses of 30 mg to achieve deeper level of sedation or if the participant showed discomfort) to achieve sedation.\n\nDeep sedation is defined as depression of the patient's consciousness such that they cannot be easily aroused but are able to respond purposefully following repeated or painful stimulation. Patients under deep sedation may have impaired ventilatory function and may require assistance maintaining a patent airway while Moderate sedation, defined as depressing the patient's consciousness while maintaining the ability to respond to verbal and tactile stimuli, is considered safe for various interventional radiology procedures. Patients under moderate sedation can maintain spontaneous respiration and a patent airway without assistance\n\nParticipants will be allowed to breathe spontaneously, and the propofol infusion rate will be titrated according to clinical response. Adequate sedation will be reached by the absence of body movements and failure to respond to verbal commands. Although participants cannot comply with breathing instructions. An oropharyngeal airway will be applied to avoid airway obstruction.\n\nIn group B, the participants will be anesthetized by the physician performing ablation. After routine disinfection and draping, 10 ml of 1% lidocaine will be injected into the skin puncture site and thyroid capsule trans-mid-neck under US guidance. If the participant suffered from severe pain, 2-5 ml of 1% lidocaine will be supplemented locally.\n\nAblation will be discontinued if participants experience unbearable pain.\n\nAll procedures will be performed by a single interventional radiologist (MD). Anesthesia will be administered by a single anesthesiologist (MD). Following asepsis protocols, the patients will undergo a procedure in which a linear ultrasound probe (10-15 MHz) LOGIQ P9 ultrasonography will be used. Microwave ablation will be done by Canyon Medical-Thyroid Ablation device.\n\nMoving shot or fixed-applicator technique will be used based on the tumor characteristics. The target for ablation for a benign nodule will be the entire nodule. Nodules that are completely solid or mixed with 90% solid components will be directly ablated. For the solid nodules containing 50-89% of solid components, the cystic portion will be aspirated using a 20-23-G puncture needle before the ablation. For nodules with \\> 50% fluid content, the fluid will be withdrawn first, followed by saline flushing and ablation. The ablation procedure will be terminated when the target lesion is completely ablated.",[26],"NOT_YET_RECRUITING","2025-11-18",{"date":62,"type":36},"2025-11-24",{"date":64,"type":21},"2025-11",{"date":66,"type":21},"2026-06",{"name":68,"class":43},"Suez University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":54,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100533434","a-prospective-trial-comparing-transoral-endoscopic-thyroidectomy-vestibular-approach-toetva-and-conventional-open-thyroidectomy-100533434","NCT06225765","A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy","Inclusion Criteria:\n\n* Benign thyroid nodule less than 4cm\n* Suspicious malignant thyroid nodule less than 2cm, suitable for transoral endoscopic surgery\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Contraindication to general anaesthesia\n* Vulnerable population (e.g. Cognitive impairment, pregnant)\n* Previous anterior neck surgery\n* Previous radiotherapy at the head and neck region\n* Malignant thyroid nodule \\> 2cm\n* Presence of another malignancy, lateral neck, or distant metastasis\n* Retrosternal goitre\n* Cervical spine disease precluding extension of the neck\n* Obesity with BMI \\> 35kg\u002Fm2\n* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention\n* Untreated active infection\n* Non-correctable coagulopathy\n* Emergency surgery",{"count":76,"type":21},40,[56],"To determine if transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a safe and effective procedure compared to traditional open thyroidectomy. Surgical outcomes, patients' satisfaction, voice and swallowing outcomes will be assessed.",[26,80],"Suspicious Malignant Thyroid Nodule",[82],"Thyroid nodule","2024-07-06",{"date":85,"type":36},"2024-07-09",{"date":87,"type":36},"2024-07-01",{"date":89,"type":21},"2026-09-30",{"name":91,"class":43},"Tseung Kwan O Hospital, Hong Kong",1]